<unk>  is a monoclonal antibody that is FDA approved for the treatment of metastatic breast cancer and as a neoadjuvant treatment of breast cancer. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include diarrhea, alopecia, neutropenia, nausea, vomiting, fatigue, rash, and peripheral neuropathy in combination with trastuzumab and docetaxel.
Pertuzumab
Bavituximab
Matuzumab
Volociximab
Caplacizumab
Elotuzumab
Idarucizumab
Risankizumab